Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.

The neuropathological substrate of dementia in patients with Parkinson's disease is still under debate, particularly in patients with insufficient alternate neuropathology for other degenerative dementias. In patients with pure Lewy body Parkinson's disease, previous post-mortem studies have shown that dopaminergic and cholinergic regulatory projection systems degenerate, but the exact pathways that may explain the development of dementia in patients with Parkinson's disease remain unclear. Studies in rodents suggest that both the mesocorticolimbic dopaminergic and septohippocampal cholinergic pathways may functionally interact to regulate certain aspects of cognition, however, whether such an interaction occurs in humans is still poorly understood. In this study, we performed stereological analyses of the A9 and A10 dopaminergic neurons and Ch1, Ch2 and Ch4 cholinergic neurons located in the basal forebrain, along with an assessment of α-synuclein pathology in these regions and in the hippocampus of six demented and five non-demented patients with Parkinson's disease and five age-matched control individuals with no signs of neurological disease. Moreover, we measured choline acetyltransferase activity in the hippocampus and frontal cortex of eight demented and eight non-demented patients with Parkinson's disease, as well as in the same areas of eight age-matched controls. All patients with Parkinson's disease exhibited a similar 80-85% loss of pigmented A9 dopaminergic neurons, whereas patients with Parkinson's disease dementia presented an additional loss in the lateral part of A10 dopaminergic neurons as well as Ch4 nucleus basalis neurons. In contrast, medial A10 dopaminergic neurons and Ch1 and Ch2 cholinergic septal neurons were largely spared. Despite variable Ch4 cell loss, cortical but not hippocampal cholinergic activity was consistently reduced in all patients with Parkinson's disease, suggesting significant dysfunction in cortical cholinergic pathways before frank neuronal degeneration. Patients with Parkinson's disease dementia were differentiated by a significant reduction in hippocampal cholinergic activity, by a significant loss of non-pigmented lateral A10 dopaminergic neurons and Ch4 cholinergic neurons (30 and 55% cell loss, respectively, compared with neuronal preservation in control subjects), and by an increase in the severity of α-synuclein pathology in the basal forebrain and hippocampus. Overall, these results point to increasing α-synuclein deposition and hippocampal dysfunction in a setting of more widespread degeneration of cortical dopaminergic and cholinergic pathways as contributing to the dementia occurring in patients with pure Parkinson's disease. Furthermore, our findings support the concept that α-synuclein deposition is associated with significant neuronal dysfunction in the absence of frank neuronal loss in Parkinson's disease.

[1]  G. Halliday,et al.  Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans , 1996, The Journal of comparative neurology.

[2]  Angie A. Kehagia,et al.  Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease , 2010, The Lancet Neurology.

[3]  H J Gundersen,et al.  The efficiency of systematic sampling in stereology and its prediction * , 1987, Journal of microscopy.

[4]  C. Marsden,et al.  l-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction , 2005, Psychopharmacology.

[5]  G. Halliday,et al.  Specific A10 Dopaminergic Nuclei in the Midbrain Degenerate in Parkinson's Disease , 1997, Experimental Neurology.

[6]  W. Oertel,et al.  Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[7]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[8]  Natalie Landeck,et al.  Characterization of Cognitive Deficits in Rats Overexpressing Human Alpha-Synuclein in the Ventral Tegmental Area and Medial Septum Using Recombinant Adeno-Associated Viral Vectors , 2013, PloS one.

[9]  G. Glosser,et al.  Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease , 2000, Neurology.

[10]  Jacques Darcourt,et al.  Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies , 2009, British Journal of Psychiatry.

[11]  J. Trojanowski,et al.  Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. , 2002, Neuron.

[12]  F. Fonnum,et al.  A rapid radiochemical method for the determination of choline acetyltransferase , 1975, Journal of neurochemistry.

[13]  R. Chervin,et al.  Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease , 2012, Annals of neurology.

[14]  D. Aarsland,et al.  Neuropathology of dementia in Parkinson's disease: A prospective, community‐based study , 2005, Annals of neurology.

[15]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[16]  G. Halliday,et al.  Selective hippocampal neuron loss in dementia with Lewy bodies , 2002, Annals of neurology.

[17]  K. Jellinger,et al.  Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. , 1991, Molecular and chemical neuropathology.

[18]  R. Oades,et al.  Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity , 1987, Brain Research Reviews.

[19]  Päivi Marjamäki,et al.  Choline acetyltransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment , 2001, Acta Neuropathologica.

[20]  S. Ikemoto Dopamine reward circuitry: Two projection systems from the ventral midbrain to the nucleus accumbens–olfactory tubercle complex , 2007, Brain Research Reviews.

[21]  B. Berger,et al.  Alterations of dopaminergic and noradrenergic innervations in motor cortex in parkinson's disease , 1991, Annals of neurology.

[22]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[23]  E. Gerhardt,et al.  Dopamine-depletion and increased α-synuclein load induce degeneration of cortical cholinergic fibers in mice , 2011, Journal of the Neurological Sciences.

[24]  J. Kaas,et al.  Topography and collateralization of the dopaminergic projections to motor and lateral prefrontal cortex in owl monkeys , 1992, The Journal of comparative neurology.

[25]  S Fahn,et al.  Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. , 1971, Journal of the neurological sciences.

[26]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[27]  G. Halliday,et al.  Comparative anatomy of the ventromedial mesencephalic tegmentum in the rat, cat, monkey and human , 1986, The Journal of comparative neurology.

[28]  Y. Agid,et al.  Acute and Long-Term Administration of Anticholinergics in Parkinson's Disease: Specific Effects on the Subcortico-Frontal Syndrome , 1999, Brain and Cognition.

[29]  A. Levey,et al.  Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia innominata), and hypothalamus in the rhesus monkey , 1983, The Journal of comparative neurology.

[30]  Bengt Winblad,et al.  Dopaminergic Deficiency is More Pronounced in Putamen than in Nucleus Caudatus in Parkinson's Disease , 1983 .

[31]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[32]  A. Simeone,et al.  Otx2 expression is restricted to dopaminergic neurons of the ventral tegmental area in the adult brain. , 2010, The International journal of developmental biology.

[33]  Relatively high levels of dopamine in nucleus accumbens of levodopa treated patients with Parkinson's disease , 2005, Journal of Neural Transmission.

[34]  T. Goldberg,et al.  Dopaminergic modulation of cortical function in patients with Parkinson's disease , 2002, Annals of neurology.

[35]  S. J. Shammah-Lagnado,et al.  Organization of ventral tegmental area projections to the ventral tegmental area–nigral complex in the rat , 2008, Neuroscience.

[36]  Roger A. Barker,et al.  Cognitive Impairment in Parkinson's Disease: The Dual Syndrome Hypothesis , 2012, Neurodegenerative Diseases.

[37]  R. Albin,et al.  Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease , 2010, Brain : a journal of neurology.

[38]  A. Bonnet,et al.  Working memory in Parkinson's disease patients: clinical features and response to levodopa. , 2008, Arquivos de neuro-psiquiatria.

[39]  M. Yahr,et al.  Dementia in idiopathic Parkinson's disease , 1986, Journal of Neural Transmission.

[40]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[41]  A. Lees,et al.  A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.

[42]  Johannes C. Klein,et al.  Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo , 2010, Neurology.

[43]  A. Lees,et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease , 1992, Neurology.

[44]  J. Trojanowski,et al.  Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies , 2013, Nature Reviews Neuroscience.

[45]  John L. Robinson,et al.  Neuropathologic substrates of Parkinson disease dementia , 2012, Annals of neurology.

[46]  S. Aalto,et al.  Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. , 2009, Parkinsonism & related disorders.

[47]  L. White,et al.  Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease , 2012, Neurology.

[48]  H. Braak,et al.  Cognitive status correlates with neuropathologic stage in Parkinson disease , 2005, Neurology.

[49]  J. Morris,et al.  Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.

[50]  Akinori Nakamura,et al.  Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. , 2002, Brain : a journal of neurology.

[51]  D. Kirik,et al.  Functional Convergence of Dopaminergic and Cholinergic Input Is Critical for Hippocampus-Dependent Working Memory , 2008, The Journal of Neuroscience.

[52]  E. Perry,et al.  Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[53]  K. Sethi,et al.  Rivastigmine for the treatment of dementia associated with Parkinson’s disease , 2007, Neuropsychiatric disease and treatment.

[54]  E. Mufson,et al.  Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson's disease: reduced cell numbers and co-localization with cholinergic neurons , 1991, Brain Research.

[55]  Glenda M. Halliday,et al.  Cortical Lewy body pathology in the diagnosis of dementia , 2001, Acta Neuropathologica.

[56]  Günther Deuschl,et al.  Rivastigmine for dementia associated with Parkinson's disease. , 2004, The New England journal of medicine.

[57]  T. Arendt,et al.  The cholinergic system in aging and neuronal degeneration , 2011, Behavioural Brain Research.

[58]  New face of neuromelanin. , 2006, Journal of neural transmission. Supplementum.

[59]  D. Kirik,et al.  Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression , 2006, Neurobiology of Disease.

[60]  Mark G. Packard,et al.  Anterograde and retrograde tracing of projections from the ventral tegmental area to the hippocampal formation in the rat , 1994, Brain Research Bulletin.

[61]  R. Albin,et al.  The cholinergic system and Parkinson disease , 2011, Behavioural Brain Research.

[62]  I. Nakano,et al.  Parhnson’s Disease: Neuron Loss in the Nucleus Basah Without Concomitant Alzheimer’s Disease , 2004 .

[63]  John A. Dani,et al.  In vitro identification and electrophysiological characterization of dopamine neurons in the ventral tegmental area , 2010, Neuropharmacology.

[64]  D. Dickson,et al.  Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies , 2010, Acta Neuropathologica.

[65]  D. Aarsland,et al.  The epidemiology of dementia associated with Parkinson disease , 2010, Journal of the Neurological Sciences.

[66]  Yves Agid,et al.  A subcortico-cortical cholinergic system is affected in Parkinson's disease , 1983, Brain Research.

[67]  C. Masters,et al.  Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria , 2002, Acta Neuropathologica.

[68]  A. Iguchi,et al.  Depletion of cholinergic neurons in the nucleus of the medial septum and the vertical limb of the diagonal band in dementia with Lewy bodies , 2006, Acta Neuropathologica.

[69]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[70]  P. R. Hof,et al.  Design-based stereology in neuroscience , 2005, Neuroscience.

[71]  Mark J. West,et al.  Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias , 1999, Trends in Neurosciences.

[72]  R. Hilker,et al.  Dementia in Parkinson disease , 2005, Neurology.

[73]  R. Gaykema,et al.  Direct catecholaminergic‐cholinergic interactions in the basal forebrain. II. Substantia nigra‐ventral tegmental area projections to cholinergic neurons , 1996, The Journal of comparative neurology.

[74]  L. Swanson,et al.  The projections of the ventral tegmental area and adjacent regions: A combined fluorescent retrograde tracer and immunofluorescence study in the rat , 1982, Brain Research Bulletin.